@article{18510,
  keywords = {Antigens, Bacterial, Drug Monitoring, Drug Therapy, Combination, Female, Glycolipids, Humans, leprosy, Male, Serologic Tests},
  author = {Prakash K and Sehgal V N and Aggarwal R},
  title = {Evaluation of phenolic glycolipid-I (PGL-I) antibody as a multidrug therapy (MDT) monitor.},
  abstract = {<p>Since phenolic glycolipid-I (PGL-I) is an unequivocal marker for Mycobacterium leprae, this antigen has been a good candidate for the serodiagnosis and monitoring of the effectiveness of leprosy chemotherapy. The present study, a continuation of an earlier report, was undertaken to estimate PGL-I antibody titers in 40 leprosy patients 3 and 6 months after starting MDT. All the leprosy groups showed significant declines in anti PGL-I reactivity after 6 months. There was a good correlation between bacteriological indices (BI) and anti PGL-I antibody levels. Thus, PGL-I based serology may be useful in monitoring the response to multidrug therapy.</p>},
  year = {1993},
  journal = {The Journal of dermatology},
  volume = {20},
  pages = {16-20},
  month = {1993 Jan},
  issn = {0385-2407},
  doi = {10.1111/j.1346-8138.1993.tb03822.x},
  language = {eng},
}